korean semaglutide How will Wegovy fit into obesity society's guidelines in Korea? < Pharma < Article Ministry OKs phase-3a clinical trial

Penna C, Pagliaro P

While early clinical trials showed manageable side effects, post-marketing surveillance has revealed more severe complications that require closer scrutiny

J.MackinK

Gastrointestinal effects: the main titration bottleneck Nausea, diarrhea, constipation, and vomiting run around 40 to 44% overall, dose-dependent in how many people report them but mild-dominant in severity: severe events stay at or below about 1.7% in any category even at the top dose. In the obesity program the by-dose rates run nausea 25/29/28%, diarrhea 19/21/23%, and vomiting 8/11/13% at 5/10/15 mg. They concentrate during escalation and ease with time on a held dose

Therefore, we focus on the biological characteristics of GLP-1, render an overview of the mechanism of GLP-1 effects in diseases, and investigate the potential of GLP-1 analogues for the treatment of related diseases in this review

The EMA notes that about 1 in 10,000 Ozempic patients may experience this rare side effect